Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 19, 2010, Pages 5847-5852

  Brugel, Todd A ^a   Smith, Reed W ^a   Balestra, Michael ^a   Becker, Christopher ^a   Daniels, Thalia ^a   Hoerter, Tiffany N ^a   Koether, Gerard M ^a   Throner, Scott R ^a   Panko, Laura M ^a   Folmer, James J ^a   Cacciola, Joseph ^a   Hunter, Angela M ^a   Liu, Ruifeng ^a   Edwards, Philip D ^a   Brown, Dean G ^a   Gordon, John ^a   Ledonne, Norman C ^a   Pietras, Mark ^a   Schroeder, Patricia ^a   Sygowski, Linda A ^a   Hirata, Lee T ^a   Zacco, Anna ^a   Peters, Matthew F ^a   more..

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antagonist; Depression; Kappa; Opioid receptor

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; BENZAMIDE DERIVATIVE; KAPPA OPIATE RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DIURESIS; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; DIURESIS; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSOMES, LIVER; RATS; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP; TROPANES;

RATTUS;

EID: 77957596306     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.113     Document Type: Article

References (20)

1. R.C. Kessler, P. Berglund, and O. Demler JAMA 289 2003 3095
2. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, and M. Fava Am. J. Psychiatry 163 2006 28
3. P.S. Portoghese, H. Nagase, A.W. Lipkowski, D.L. Larson, and A.E. Takemori J. Med. Chem. 31 1988 836
4. J.B. Thomas, R.N. Atkinson, R.B. Rothman, S.E. Fix, S.W. Mascarella, N.A. Vinson, H. Xu, C.M. Dersch, Y. Lu, B.E. Cantrell, D.M. Zimmerman, and F.I. Carroll J. Med. Chem. 44 2001 2687
5. S.D. Nague, A.M. Pliakas, M.S. Todtenkopg, H.C. Tomasiewicz, Y. Zhang, W.C. Stevens Jr., R.M. Jones, P.S. Portoghese, and W.A. Carlezon Jr. J. Pharmacol. Exp. Ther. 305 2003 323
6. J.P. McLaughlin, M. Maron-Popovici, and C. Chavkin J. Neurosci. 23 2003 5674
7. A.T. Knoll, E.G. Meloni, J.B. Thomas, F.I. Carroll, and W.A. Carlezon J. Pharmacol. Exp. Ther. 323 2007 838
8. W.A. Carlezon Jr., C. Beguin, J.A. DiNieri, M.H. Baumann, M.R. Richards, M.S. Todtenkopf, R.B. Rothman, Z. Ma, D.Y. Lee, and B.M. Cohen J. Pharmacol. Exp. Ther. 316 2006 440
9. 1H NMR and LCMS analysis.
10. 50's for κ and μ functional agonism for select compounds in this report were all >30 μM.
11. K. Schroeder, B. Neagle, D.J. Trezise, and J. Worley J. Biomol. Screening 8 2003 50
12. S. Bhattacharyya Tetrahedron Lett. 35 1994 2401
13. R. Robinson J. Chem. Soc., Trans. 111 1917 762
14. M. Suzuki, Y. Ohuchi, H. Asanuma, T. Kaneko, S. Yokomori, C. Ito, Y. Isobe, and M. Uramatsu Chem. Pharm. Bull. 49 2001 29
15. Absolute configurations of 9i, 9j and 9l were determined using vibrational circular dichroism (VCD). For a review of VCD see: L.A. Nodie, and R.K. Dukor D.E. Pivonka, J.M. Chalmers, P.R. Griffiths, Applications of Vibrational Spectroscopy in Pharmaceutical Research and Development 2007 John Wiley Chichester 129 154
16. Absolute configuration assignments based on GTPγS data in conjunction with VCD results for 9i, 9j and 9l.
17. See the Supplementary data section for a method description for the κ pharmacophore model.
18. T.G. Metzger, M.G. Paterlini, P.S. Portoghese, and D.M. Ferguson Neurochem. Res. 21 1996 1287
19. H.B. Gottlieb, K.J. Varner, V.A. Kenigs, A.M. Cabral, and D.R. Kapusta J. Pharmacol. Exp. Ther. 312 2005 678
20. See the Supplementary data section for a detailed description of the diuresis results for 6c. A companion manuscript describing efficacy in an anxiety/depression-like animal model for 6c (termed MTAB) is in preparation (Peters, M.F. et al.).